Army sbir phase II
Ended Definitive Contract Awarded Last action
- Contract number
- W911QY20C0003
- Awardee
-
CMC Pharmaceuticals, Inc. UEI R9AVS7XL2YB4
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $1,466,683
Award facts
- Contract value 100% obligated
- $1,466,682.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Cleveland, OH 44103, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Additional Work (new agreement, FAR part 6 applies) | $504,142 | |
| Exercise an Option | $336,314 | |
| Other Administrative Action | $0 | |
| Original award | $626,227 |
About this award
The U.S. Army awarded CMC Pharmaceuticals, Inc., a small business located in Cleveland, Ohio, a $1.47 million Small Business Innovation Research (SBIR) Phase II contract on October 30, 2019, with completion targeted for May 3, 2022. This firm fixed-price contract was set aside exclusively for small businesses and funded through the Joint Program Executive Office for Chemical and Biological Defense. CMC Pharmaceuticals specializes in pharmaceutical formulation development and complex drug delivery systems, with demonstrated expertise supporting Department of Defense and U.S. Special Operations Command requirements through previous SBIR Phase I and Phase II awards focused on formulating and testing critical pharmaceutical products.
The SBIR program supports innovative research and development by small businesses to address federal agency technical needs. This Phase II expansion award represents continued investment in CMC Pharmaceuticals' capabilities to advance pharmaceutical product development, building on successful Phase I research outcomes. The company's track record includes formulation work on atropine sulfate and scopolamine hydrobromide products, as well as sustained-release drug delivery systems, positioning it as a specialized contractor for the Department of Defense's chemical and biological defense initiatives.
Quick answers
Who was awarded contract W911QY20C0003?
W911QY20C0003 was awarded to CMC Pharmaceuticals, Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on October 30, 2019.
How much is contract W911QY20C0003 worth?
The government has obligated $1,466,683 on W911QY20C0003.
Which agency awarded contract W911QY20C0003?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911QY20C0003, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911QY20C0003 competed?
The extent of competition for W911QY20C0003 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award